Corcept Therapeutics (CORT) Interest Expenses (2010 - 2017)
Corcept Therapeutics recorded quarterly Interest Expenses of $98000.0 in Q2 2017, down 56.44% quarter-over-quarter from $225000.0 in Q1 2017, and down 81.54% year-over-year from $531000.0 in Q2 2016.
Corcept Therapeutics' Interest Expenses history runs 8 years deep, the most recent figure standing at $98000.0 for Q2 2017.
- In Q2 2017, Interest Expenses fell 81.54% year-over-year to $98000.0; the TTM figure through Mar 2018 stood at $98000.0 (down 94.07% YoY), while the FY2016 annual figure was $2.0 million, down 31.23% from the prior year.
- Interest Expenses came in at $98000.0 for Q2 2017 at Corcept Therapeutics, down from $225000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $1.2 million in Q3 2013 to a low of $98000.0 in Q2 2017.
- A 5-year average of $755833.3 and a median of $785000.0 in 2015 frame the typical range for Interest Expenses.
- Across the five-year window, Interest Expenses soared 22720.0% in 2013 and sank 81.54% in 2017, its largest moves.
- Corcept Therapeutics' Interest Expenses stood at $1.1 million in 2013, then dropped by 25.23% to $818000.0 in 2014, then dropped by 15.4% to $692000.0 in 2015, then slumped by 40.75% to $410000.0 in 2016, then tumbled by 76.1% to $98000.0 in 2017.
- According to Business Quant data, Interest Expenses over the past three periods registered $98000.0, $225000.0, and $410000.0 for Q2 2017, Q1 2017, and Q4 2016 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Corcept Therapeutics | 7.26 Bn | 6.92 Bn | 162.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 98,000.00 |
| Jun 30, 2017 | 98,000.00 |
| Mar 31, 2017 | 225,000.00 |
| Mar 31, 2017 | 225,000.00 |
| Dec 31, 2016 | 410,000.00 |
| Dec 31, 2016 | 410,000.00 |
| Sep 30, 2016 | 487,000.00 |
| Sep 30, 2016 | 487,000.00 |
| Jun 30, 2016 | 531,000.00 |
| Jun 30, 2016 | 531,000.00 |
| Mar 31, 2016 | 611,000.00 |
| Mar 31, 2016 | 611,000.00 |
| Dec 31, 2015 | 692,000.00 |
| Dec 31, 2015 | 692,000.00 |
| Sep 30, 2015 | 703,000.00 |
| Sep 30, 2015 | 703,000.00 |
| Jun 30, 2015 | 770,000.00 |
| Jun 30, 2015 | 770,000.00 |
| Mar 31, 2015 | 800,000.00 |
| Mar 31, 2015 | 800,000.00 |
| Dec 31, 2014 | 818,000.00 |
| Dec 31, 2014 | 818,000.00 |
| Sep 30, 2014 | 903,000.00 |
| Sep 30, 2014 | 903,000.00 |
| Jun 30, 2014 | 971,000.00 |
| Jun 30, 2014 | 971,000.00 |
| Mar 31, 2014 | 1.07 Mn |
| Mar 31, 2014 | 1.07 Mn |
| Dec 31, 2013 | 1.09 Mn |
| Dec 31, 2013 | 1.09 Mn |
| Sep 30, 2013 | 1.17 Mn |
| Sep 30, 2013 | 1.17 Mn |
| Jun 30, 2013 | 1.11 Mn |
| Jun 30, 2013 | 1.11 Mn |
| Mar 31, 2013 | 1.14 Mn |
| Mar 31, 2013 | 1.14 Mn |
| Dec 31, 2012 | 1.14 Mn |
| Dec 31, 2012 | 1.14 Mn |
| Sep 30, 2012 | 622,000.00 |
| Sep 30, 2012 | 622,000.00 |
| Jun 30, 2012 | 5,000.00 |
| Jun 30, 2012 | 5,000.00 |
| Mar 31, 2012 | 5,000.00 |
| Mar 31, 2012 | 5,000.00 |
| Dec 31, 2011 | 8,000.00 |
| Dec 31, 2011 | 8,000.00 |
| Sep 30, 2011 | 1,000.00 |
| Sep 30, 2011 | 1,000.00 |
| Jun 30, 2011 | 12,000.00 |
| Jun 30, 2011 | 12,000.00 |
| Mar 31, 2011 | 5,000.00 |
| Mar 31, 2011 | 5,000.00 |
| Dec 31, 2010 | 7,000.00 |
| Dec 31, 2010 | 7,000.00 |
| Sep 30, 2010 | 3,000.00 |
| Sep 30, 2010 | 3,000.00 |
| Jun 30, 2010 | 3,000.00 |
| Jun 30, 2010 | 3,000.00 |